TNF-α-induced Tim-3 expression marks the dysfunction of infiltrating natural killer cells in human esophageal cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
TNF-α-induced Tim-3 expression marks the dysfunction of infiltrating natural killer cells in human esophageal cancer
Authors
Keywords
-
Journal
Journal of Translational Medicine
Volume 17, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-05-22
DOI
10.1186/s12967-019-1917-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL
- (2018) Frank Vari et al. BLOOD
- Endoscopic Management of Early Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus: Screening, Diagnosis, and Therapy
- (2018) Massimiliano di Pietro et al. GASTROENTEROLOGY
- Efficacy of endoscopic screening for esophageal cancer in China (ESECC): design and preliminary results of a population-based randomised controlled trial
- (2018) Zhonghu He et al. GUT
- Tim-3 and its role in regulating anti-tumor immunity
- (2017) Madhumita Das et al. IMMUNOLOGICAL REVIEWS
- CD56bright NK cells exhibit potent antitumor responses following IL-15 priming
- (2017) Julia A. Wagner, Maximillian Rosario, Rizwan Romee, Melissa M. Berrien-Elliott, Stephanie E. Schneider, Jeffrey W. Leong, Ryan P. Sullivan, Brea A. Jewell, Michelle Becker-Hapak, Timothy Schappe, Sara Abdel-Latif, Aaron R. Ireland, Devika Jaishankar, Justin A. King, Ravi Vij, Dennis Clement, Jodie Goodridge, Karl-Johan Malmberg, Hing C. Wong, Todd A. Fehniger JOURNAL OF CLINICAL INVESTIGATION
- Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers
- (2017) Y Liu et al. ONCOGENE
- IL-21-mediated reversal of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-deficient tumours
- (2017) Hyungseok Seo et al. Nature Communications
- TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
- (2017) Florie Bertrand et al. Nature Communications
- High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy
- (2016) Suresh Gopi Kalathil et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Tim-3 Expression on Tumor-Infiltrating PD-1 + CD8 + T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma
- (2016) Clémence Granier et al. CANCER RESEARCH
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- Targeting natural killer cells in cancer immunotherapy
- (2016) Camille Guillerey et al. NATURE IMMUNOLOGY
- Tim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages
- (2015) Wenjiang Yan et al. GUT
- The Clinical Significance of Abnormal Tim-3 Expression on NK Cells from Patients with Gastric Cancer
- (2015) Zhenxin Wang et al. IMMUNOLOGICAL INVESTIGATIONS
- Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma
- (2015) Liyun Xu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Low expression of Bin1, along with high expression of IDO in tumor tissue and draining lymph nodes, are predictors of poor prognosis for esophageal squamous cell cancer patients
- (2015) Yunlong Jia et al. INTERNATIONAL JOURNAL OF CANCER
- T-cell exhaustion in the tumor microenvironment
- (2015) Y Jiang et al. Cell Death & Disease
- Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer
- (2015) Christine Pasero et al. Oncotarget
- PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer
- (2015) J. J. Severson et al. Cancer Immunology Research
- TIMgenes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity
- (2015) Gordon J. Freeman et al. IMMUNOLOGICAL REVIEWS
- CD56brightPerforinlow Noncytotoxic Human NK Cells Are Abundant in Both Healthy and Neoplastic Solid Tissues and Recirculate to Secondary Lymphoid Organs via Afferent Lymph
- (2014) P. Carrega et al. JOURNAL OF IMMUNOLOGY
- Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
- (2014) I. P. da Silva et al. Cancer Immunology Research
- Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors
- (2013) S. Rusakiewicz et al. CANCER RESEARCH
- Phenotype and Function of T Cells Infiltrating Visceral Metastases from Gastrointestinal Cancers and Melanoma: Implications for Adoptive Cell Transfer Therapy
- (2013) S. Turcotte et al. JOURNAL OF IMMUNOLOGY
- Tumor-Specific T Cells in Human Merkel Cell Carcinomas: A Possible Role for Tregs and T-Cell Exhaustion in Reducing T-Cell Responses
- (2013) Mitra Dowlatshahi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Tim-3: An Activation Marker and Activation Limiter of Innate Immune Cells
- (2013) Gencheng Han et al. Frontiers in Immunology
- Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity
- (2012) L. C. Ndhlovu et al. BLOOD
- Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9
- (2012) M. K. Gleason et al. BLOOD
- Cancer-Related Inflammation
- (2012) Juliana Candido et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Profound Coordinated Alterations of Intratumoral NK Cell Phenotype and Function in Lung Carcinoma
- (2011) S. Platonova et al. CANCER RESEARCH
- Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity
- (2011) Emilie Mamessier et al. JOURNAL OF CLINICAL INVESTIGATION
- NK cell dysfunction with down-regulated CD16 and up-regulated CD56 molecules in patients with esophageal squamous cell carcinoma
- (2010) M. Watanabe et al. DISEASES OF THE ESOPHAGUS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started